1.47
+0.04(+2.80%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.45 |
| Day High | 1.48 |
| Day Low | 1.35 |
| 52-Week High | 3.7 |
| 52-Week Low | 0.66 |
| Volume | 1.05M |
| Average Volume | 5.24M |
| Market Cap | 169.36M |
| PE | -16.33 |
| EPS | -0.09 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.56 |
| Change | 0.04 |
If you invested $1000 in Coherus BioSciences, Inc. (CHRS) 10 years ago, it would be worth $93.75 as of December 26, 2024 at a share price of $1.47. Whereas If you bought $1000 worth of Coherus BioSciences, Inc. (CHRS) shares 5 years ago, it would be worth $79.16 as of December 26, 2024 at a share price of $1.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
GlobeNewswire Inc.
Dec 18, 2024 1:30 PM GMT
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS)
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
GlobeNewswire Inc.
Dec 03, 2024 12:00 PM GMT
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 9:01 PM GMT
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Deve